Lyfgenia and Casgevy: Shaping the Future of Sickle Cell Disease Treatment
The treatment landscape for sickle cell disease (SCD) has entered a new era with the launch of two innovative gene therapies—Lyfgenia and Casgevy. Both represent groundbreaking advances, but their methods and risks set them apart. Lyfgenia relies on a lentiviral vector to deliver a healthy gene into a patient’s stem cells to curb the sickling of red blood cells. However, challenges...
0 Comments 0 Shares 32 Views 0 Reviews
Sponsored